Compare DexCom, Inc. (DXCM) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Tidewater Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Tidewater Inc trades at $85.42 (market cap $4.21B). The key difference: DexCom, Inc. is far larger — about 7.6× Tidewater Inc's market cap, and Tidewater Inc is more actively traded (590,005 versus 3,607,070). Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Tidewater Inc for 26 Days on average.
| DXCM | TDW | |
|---|---|---|
Market Cap | $31.86B | $4.21B |
Volume | 3,607,070 | 590,005 |
Sector | Health | Energy |
52-Week High | $92.34 | $100.61 |
52-Week Low | $54.84 | $47.29 |
Typical Hold Time | 62 Days | 26 Days |
Enterprise Value | $31.32B | $4.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
Tidewater (TDW) trades at $84.70, up 1.56% with a bullish technical signal supported by moving averages. The company maintains strong profitability with 18.34% net margins and 19.49% ROE, though recent quarterly earnings missed expectations. Recent acquisition of Wilson Sons Ultratug expands offshore services capabilities while institutional interest grows with BlackRock's $503 million investment.
The stock offers 24% upside to consensus price target of $105.50 with mixed analyst sentiment (27% buy, 58% hold). Key risks include execution of recent acquisition integration and volatile energy market conditions. Earnings growth remains the primary catalyst for sustained price appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
